Highlights

Gross sales reached approximately AUD 25 million since launch in January 2025.

Over 2,300 unique prescribers in June 2025; refill rates exceed industry norms.

More than 16,000 prescriptions filled for 6,700 patients across the US.

Botanix Pharmaceuticals Ltd (ASX:BOT), a clinical dermatology company, has reported promising initial results from the commercial rollout of Sofdra™ (sofpironium) topical gel, 12.45%, its new treatment for primary axillary hyperhidrosis. Since the January 2025 launch, Sofdra has generated gross sales of approximately AUD 25 million, with consistent month-on-month growth through June.

The product demonstrated market uptake, with over 2,300 unique healthcare providers prescribing Sofdra in June alone. The total prescription volume has now surpassed 16,000, dispensed to over 6,700 individual patients since launch. Refill activity has also been notable—patients who started therapy in February have averaged 3.4 prescription fills, significantly above the industry average of 2 fills per year.

Patients enrolled in the auto-refill program showed a 95% adherence rate, while the overall adherence rate stood at 79%. These metrics reflect the product’s positive reception and ease of access via the Botanix Fulfilment Platform.

Botanix also reported encouraging gross-to-net (GTN) yield progress, achieving a 23% GTN yield by June, with the figure tracking against top U.S. dermatology peers. The Company has set a GTN yield target range of 30–40% going forward.

To build on the current growth momentum, Botanix is investing in expanding its commercial footprint. Initially launched in 27 territories across three regions, the company expanded to 33 territories in Q1 FY2026 and is now preparing to scale up further to 50 territories across five regions in Q2 FY2026. Recruitment for two additional regional managers is already underway.

Marketing efforts have been broadened with the development of new sales materials for healthcare provider offices and the continued expansion of the Botanix telehealth platform to reach a wider patient audience. Educational initiatives also support prescriber adoption, including the “Summer of Sweat” roadshow spanning 14 major U.S. cities, and peer-to-peer speaker programs featuring scientific insights and clinical evidence. Sofdra’s Phase 3 clinical data has recently been published in the Journal of the American Academy of Dermatology (JAAD).

Despite these commercial milestones, BOT shares fell by 53% to AUD 0.145 on 8 July 2025. No formal statement has been released addressing the market reaction.